What is Item 9 Labs's earnings per share (EPS)?

Item 9 Labs (INLB) reported diluted earnings per share of -$0.33 for fiscal year 2022. This represents a -135.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Item 9 Labs Financials

INLB

FY2022 annual

Revenue $21.8M -0.8% YoY

Net Income -$31.2M -185.9% YoY

EPS (Diluted) -$0.33 -135.7% YoY

Free Cash Flow -$6.6M +20.0% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2023, ended Jun 30, 2023 Reported Aug 21, 2023 Currency USD FYE September

Item 9 Labs (INLB) reported $21.8M in revenue for fiscal year 2022, down 0.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI INLB FY2022 2026-08-30

Item 9 Labs shows thin liquidity and capital-heavy losses despite largely flat revenue after FY2021.

In FY2022, net income was -$31.2M while operating cash flow was -$2.3M, revealing an earnings-to-cash mismatch rather than a simple read-through from reported losses to operating cash needs. This gap suggests noncash charges, financing costs, or working-capital effects materially shaped earnings; capital expenditures of $4.3M also kept free cash flow below operating cash flow.

Revenue was nearly unchanged from FY2021 to FY2022, but gross margin fell from 39.3% to 33.6%; the deterioration therefore reflects weaker economics per reported dollar, not simply slower sales. Operating losses expanded disproportionately, indicating that existing scale did not absorb the cost base.

The balance sheet’s short-term structure was strained: current liabilities reached $40.6M while current assets were only $3.6M. That imbalance left a current ratio of 0.1x, while reported cash and investments equaled only 0.5 months of the latest annual operating outflow.

Financial Health Signals

Financial health score not available

Item 9 Labs does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-1.71

Item 9 Labs scores -1.71, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($10K) relative to total liabilities ($48.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak

3/9

Item 9 Labs passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Item 9 Labs reported a net loss of $31.2M while operations used $2.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Item 9 Labs reported an operating loss of $23.1M against $6.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$21.8M

YoY-0.8%

5Y CAGR+186.3%

Item 9 Labs generated $21.8M in revenue in fiscal year 2022. This represents a decrease of 0.8% from the prior year.

EBITDA

-$21.5M

YoY-375.2%

Item 9 Labs's EBITDA was -$21.5M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 375.2% from the prior year.

Net Income

-$31.2M

YoY-185.9%

Item 9 Labs reported -$31.2M in net income in fiscal year 2022. This represents a decrease of 185.9% from the prior year.

EPS (Diluted)

-$0.33

YoY-135.7%

Item 9 Labs earned -$0.33 per diluted share (EPS) in fiscal year 2022. This represents a decrease of 135.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$6.6M

YoY+20.0%

Item 9 Labs recorded an outflow of $6.6M in free cash flow in fiscal year 2022, representing a cash shortfall after capex. This represents an increase of 20.0% from the prior year.

Cash & Debt

$86K

YoY-94.1%

5Y CAGR+15.5%

10Y CAGR+76.0%

Item 9 Labs held $86K in cash against $7.2M in long-term debt as of fiscal year 2022.

Shares Outstanding

100M

YoY+5.4%

5Y CAGR+6.7%

Item 9 Labs had 100M shares outstanding in fiscal year 2022. This represents an increase of 5.4% from the prior year.

Dividends Per Share

Not reported for fiscal year 2022.

Margins & Returns

Gross Margin

33.6%

YoY-5.6pp

5Y CAGR+37.4pp

Item 9 Labs's gross margin was 33.6% in fiscal year 2022, indicating the percentage of revenue retained after direct costs. This is down 5.6 percentage points from the prior year.

Return on Equity

-50.3%

YoY-37.6pp

Item 9 Labs's ROE was -50.3% in fiscal year 2022, measuring profit generated per dollar of shareholder equity. This is down 37.6 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2022: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2022: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

Capital Expenditures

$4.3M

YoY+93.0%

5Y CAGR+264.7%

Item 9 Labs invested $4.3M in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents an increase of 93.0% from the prior year.

R&D Spending

Not reported for fiscal year 2022.

Share Buybacks

Not reported for fiscal year 2022.

INLB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

INLB quarterly income statement

Metric	TTM	FY22	FY21	FY20	FY19	FY18	FY15	FY14	FY13	FY12	FY11	FY10
Revenue	$19.7M	$21.8M-0.8%	$21.9M+170.1%	$8.1M+64.6%	$4.9M+252.0%	$1.4M	$113K-37.0%	$179K-47.5%	$342K-61.7%	$892K+1759.3%	$48K	N/A
Cost of Revenue	$9.9M	$14.4M+8.4%	$13.3M+176.1%	$4.8M+88.8%	$2.6M+151.1%	$1.0M	$117K+1.4%	$116K-19.6%	$144K-62.9%	$388K+271.5%	$104K	N/A
Gross Profit	$9.8M	$7.3M-15.1%	$8.6M+161.3%	$3.3M+38.6%	$2.4M+519.6%	$384K	-$4K-106.7%	$64K-67.8%	$198K-60.7%	$504K+938.4%	-$60K	N/A
SG&A Expenses	$9.4M	$10.3M+54.6%	$6.6M+60.9%	$4.1M+66.4%	$2.5M+776.6%	$283K	N/A	$962K-26.6%	$1.3M-68.1%	$4.1M+127.8%	$1.8M	N/A
Operating Income	-$20.2M	-$23.1M-311.8%	-$5.6M-3.2%	-$5.4M+46.5%	-$10.1M-1451.0%	-$654K	N/A	N/A	N/A	-$4.1M-10862.2%	-$37K-61.8%	-$23K
Interest Expense	$9.2M	$6.4M+21.1%	$5.3M-23.9%	$7.0M+1930.7%	$343K+21468.2%	$2K	$1K-93.3%	$17K-99.1%	$1.8M+521.9%	$284K-41.7%	$486K	N/A
Income Tax	N/A	$13K	N/A	-$86K	N/A	$89K	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$31.1M	-$31.2M-185.9%	-$10.9M+11.3%	-$12.3M-23.6%	-$9.9M-1344.5%	-$689K	N/A	N/A	N/A	-$4.1M-10926.5%	-$37K-60.9%	-$23K
EPS (Diluted)	-$0.32	-$0.33-135.7%	-$0.14	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Revenue	$5.0M-11.3%	$5.7M+13.2%	$5.0M+25.1%	$4.0M-18.9%	$4.9M-25.7%	$6.6M+7.3%	$6.2M+1.5%	$6.1M
Cost of Revenue	$2.2M+13.3%	$1.9M-18.4%	$2.4M-29.0%	$3.4M+0.4%	$3.3M-15.6%	$4.0M+4.6%	$3.8M-21.0%	$4.8M
Gross Profit	$2.8M-24.2%	$3.7M+41.8%	$2.6M+306.0%	$646K-59.4%	$1.6M-40.6%	$2.7M+11.6%	$2.4M+84.3%	$1.3M
SG&A Expenses	$2.7M+20.5%	$2.2M+0.6%	$2.2M-8.4%	$2.4M-10.9%	$2.7M-12.2%	$3.1M+42.1%	$2.2M-18.4%	$2.6M
Operating Income	-$3.0M-128.9%	-$1.3M+18.3%	-$1.6M+88.9%	-$14.3M-271.9%	-$3.8M-38.8%	-$2.8M-29.9%	-$2.1M+61.2%	-$5.5M
Interest Expense	$3.0M+40.0%	$2.1M+26.8%	$1.7M-33.0%	$2.5M+52.7%	$1.6M+48.1%	$1.1M-9.3%	$1.2M-65.3%	$3.5M
Income Tax	-$1K-139.7%	$4K-3.2%	$4K	N/A	$5K+39.1%	$3K	N/A	N/A
Net Income	-$5.9M-73.6%	-$3.4M-4.9%	-$3.2M+82.4%	-$18.5M-237.4%	-$5.5M-41.4%	-$3.9M-15.8%	-$3.3M+63.0%	-$9.0M
EPS (Diluted)	-$0.06-100.0%	-$0.030.0%	-$0.03+85.0%	-$0.20-233.3%	-$0.06-50.0%	-$0.040.0%	-$0.04+63.6%	-$0.11

Not reported in any period shown, so not listed: R&D Expenses.

INLB Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

INLB quarterly balance sheet

Metric	FY22	FY21	FY20	FY19	FY18	FY15	FY14	FY13	FY12	FY11	FY10
Total Assets	$110.8M-5.2%	$116.8M+465.3%	$20.7M+42.8%	$14.5M+187.0%	$5.0M	$113K-77.9%	$509K+15.0%	$442K-61.2%	$1.1M+38.3%	$824K+3957.6%	$20K
Current Assets	$3.6M-64.8%	$10.1M+249.1%	$2.9M-2.4%	$3.0M-9.1%	$3.3M	$96K-50.3%	$194K+65.3%	$117K-84.5%	$756K+267.9%	$206K+912.9%	$20K
Cash & Equivalents	$86K-94.1%	$1.5M+1617.7%	$85K-85.3%	$575K-65.7%	$1.7M	$42K-2.0%	$43K+113.5%	$20K+1324.4%	$1K-99.3%	$192K+63905.7%	$300
Inventory	$2.5M-61.4%	$6.4M+197.7%	$2.1M	N/A	N/A	$45K-36.5%	$72K+39.3%	$51K+342.2%	$12K+223.1%	$4K	N/A
Accounts Receivable	$586K-59.5%	$1.4M+310.7%	$353K-19.3%	$437K+348.8%	$97K	$530-83.1%	$3K-91.0%	$35K-94.3%	$611K	N/A	N/A
Goodwill	$58.2M+0.3%	$58.1M+5101.1%	$1.1M0.0%	$1.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$48.8M+59.0%	$30.7M+142.8%	$12.6M+77.2%	$7.1M+187.7%	$2.5M	$5.1M+62.1%	$3.1M-7.0%	$3.4M-4.6%	$3.5M+36.2%	$2.6M-8.4%	$2.8M
Current Liabilities	$40.6M+170.8%	$15.0M+45.7%	$10.3M+44.1%	$7.1M+627.5%	$981K	$1.9M-38.9%	$3.1M+56.3%	$2.0M-41.6%	$3.4M+55.9%	$2.2M+4945.6%	$43K
Long-Term Debt	$7.2M-51.8%	$15.0M+573.9%	$2.2M	N/A	$1.5M	N/A	N/A	N/A	$100K	N/A	N/A
Total Equity	$62.0M-28.0%	$86.1M+974.2%	$8.0M+9.3%	$7.3M+186.3%	$2.6M	-$5.0M-89.1%	-$2.6M+10.3%	-$2.9M-22.2%	-$2.4M-27.5%	-$1.9M+33.2%	-$2.8M
Retained Earnings	-$65.0M-91.9%	-$33.9M-47.5%	-$23.0M-114.8%	-$10.7M-1129.0%	-$870K	-$36.8M-14.8%	-$32.1M-113.8%	-$15.0M-28.4%	-$11.7M-54.0%	-$7.6M	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Total Assets	$112.0M-1.8%	$114.1M-0.5%	$114.7M+3.5%	$110.8M-8.1%	$120.5M-0.3%	$120.9M+3.3%	$117.0M+0.2%	$116.8M
Current Assets	$3.3M-9.1%	$3.7M+29.3%	$2.8M-19.9%	$3.6M-37.6%	$5.7M-17.3%	$6.9M-17.9%	$8.4M-16.9%	$10.1M
Cash & Equivalents	$183K+81.3%	$101K+364.4%	$22K-74.6%	$86K+293.2%	$22K-74.6%	$86K-46.7%	$161K-89.0%	$1.5M
Inventory	$1.9M-28.1%	$2.6M+36.3%	$1.9M-21.4%	$2.5M-40.3%	$4.1M-14.3%	$4.8M-8.3%	$5.3M-17.8%	$6.4M
Accounts Receivable	$968K+62.5%	$596K-1.1%	$602K+2.7%	$586K-0.9%	$592K-49.7%	$1.2M-27.5%	$1.6M+12.0%	$1.4M
Goodwill	$58.1M-0.3%	$58.2M0.0%	$58.2M0.0%	$58.2M0.0%	$58.2M0.0%	$58.2M+0.3%	$58.1M0.0%	$58.1M
Total Liabilities	$59.4M+5.2%	$56.4M+3.9%	$54.3M+11.2%	$48.8M+16.2%	$42.0M+10.3%	$38.1M+17.0%	$32.6M+6.0%	$30.7M
Current Liabilities	$58.8M+24.8%	$47.1M+1.2%	$46.6M+14.8%	$40.6M+2.8%	$39.5M+10.9%	$35.6M+126.2%	$15.7M+5.0%	$15.0M
Long-Term Debt	N/A	$7.2M+9.6%	$6.6M-8.4%	$7.2M+398.1%	$1.4M-11.9%	$1.6M-89.9%	$16.3M+8.7%	$15.0M
Total Equity	$52.6M-8.7%	$57.7M-4.4%	$60.4M-2.6%	$62.0M-21.1%	$78.5M-5.1%	$82.7M-2.0%	$84.5M-1.9%	$86.1M
Retained Earnings	-$77.6M-8.2%	-$71.7M-5.0%	-$68.3M-5.0%	-$65.0M-39.6%	-$46.6M-13.3%	-$41.1M-10.4%	-$37.2M-9.9%	-$33.9M

INLB Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

INLB quarterly cash flow statement

Metric	TTM	FY22	FY21	FY20	FY19	FY18	FY15	FY14	FY13	FY12	FY11	FY10
Operating Cash Flow	N/A	-$2.3M+62.4%	-$6.0M-424.8%	-$1.1M+52.3%	-$2.4M-146.2%	-$972K	N/A	-$739K-108.9%	-$354K+63.4%	-$966K-2292.8%	-$40K-170.6%	-$15K
Capital Expenditures	N/A	$4.3M+93.0%	$2.2M+1241.4%	$167K-97.2%	$6.0M+1665.4%	$340K	$7K-58.1%	$16K-55.0%	$36K+79.6%	$20K+1206.0%	$2K	N/A
Free Cash Flow	N/A	-$6.6M+20.0%	-$8.2M-529.1%	-$1.3M+84.4%	-$8.4M-540.0%	-$1.3M	N/A	-$755K-93.9%	-$389K+60.5%	-$986K-2253.5%	-$42K	N/A
Investing Cash Flow	N/A	-$5.2M-31.7%	-$3.9M-341.8%	-$887K+88.7%	-$7.8M-2061.2%	-$363K	-$7K+58.1%	-$16K+55.0%	-$36K+62.5%	-$95K-21.6%	-$78K	N/A
Financing Cash Flow	N/A	$6.0M-46.4%	$11.3M+633.2%	$1.5M-83.2%	$9.1M+205.0%	$3.0M	N/A	$777K+90.7%	$408K-53.2%	$870K+2071.8%	$40K+163.3%	$15K

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Operating Cash Flow	$150K	N/A	N/A	-$238K+82.2%	-$1.3M-308.0%	$642K+339.6%	-$268K-130.2%	$888K
Capital Expenditures	$63K	N/A	N/A	$1.4M+20543.0%	$7K-99.1%	$743K-70.2%	$2.5M+11672.9%	-$21K
Free Cash Flow	$87K	N/A	N/A	-$1.6M-22.8%	-$1.3M-1225.9%	-$101K+96.3%	-$2.8M-418.5%	$867K
Investing Cash Flow	-$63K	N/A	N/A	-$1.4M-20277.0%	-$7K+99.7%	-$2.6M-78.8%	-$1.4M-2079.9%	-$66K
Financing Cash Flow	-$5K	N/A	N/A	$1.3M-0.4%	$1.3M-31.9%	$1.9M+354.2%	$413K+23.0%	$336K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

INLB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

INLB quarterly financial ratios

Metric	FY22	FY21	FY20	FY19	FY18	FY15	FY14	FY13	FY12	FY11	FY10
Gross Margin	33.6%-5.6pp	39.3%-1.3pp	40.6%-7.6pp	48.2%+20.8pp	27.4%	-3.8%-39.4pp	35.6%-22.4pp	58.0%+1.4pp	56.5%	-125.4%	N/A
Operating Margin	-106.0%	-25.5%+41.3pp	-66.8%	-205.5%	-46.6%	N/A	N/A	N/A	-459.6%	-78.0%	N/A
Net Margin	-143.3%	-49.7%	-151.4%	-201.6%	-49.1%	N/A	N/A	N/A	-459.6%	-77.5%	N/A
Return on Equity	-50.3%-37.6pp	-12.7%+140.8pp	-153.4%-17.8pp	-135.6%-108.7pp	-26.9%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-28.1%-18.8pp	-9.3%+50.2pp	-59.5%+9.2pp	-68.7%-55.1pp	-13.7%	N/A	N/A	N/A	-359.9%-355.4pp	-4.5%+109.3pp	-113.9%
Current Ratio	0.09-0.6x	0.67+0.4x	0.28-0.1x	0.42-2.9x	3.32	0.050.0x	0.060.0x	0.06-0.2x	0.22+0.1x	0.09-0.4x	0.47
Debt-to-Equity	0.12-0.1x	0.17-0.1x	0.28-0.7x	0.97+0.4x	0.59	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	-30.3%+7.3pp	-37.5%-21.4pp	-16.1%	-170.3%	-93.6%	N/A	-420.4%	-113.8%	-110.5%	-87.3%	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Gross Margin	56.1%-9.5pp	65.7%+13.3pp	52.4%+36.3pp	16.1%-16.1pp	32.2%-8.1pp	40.3%+1.6pp	38.8%+17.4pp	21.3%
Operating Margin	-59.1%-36.2pp	-22.9%+8.8pp	-31.7%	-357.6%	-78.0%-36.3pp	-41.8%-7.3pp	-34.5%+55.8pp	-90.3%
Net Margin	-117.8%	-60.2%+4.7pp	-64.9%	-461.9%	-111.1%	-58.3%-4.3pp	-54.1%	-148.4%
Return on Equity	-11.2%-5.3pp	-5.9%-0.5pp	-5.4%+24.5pp	-29.8%-22.9pp	-7.0%-2.3pp	-4.7%-0.7pp	-4.0%+6.5pp	-10.5%
Return on Assets	-5.3%-2.3pp	-3.0%-0.2pp	-2.8%+13.9pp	-16.7%-12.2pp	-4.5%-1.3pp	-3.2%-0.3pp	-2.9%+4.9pp	-7.7%
Current Ratio	0.060.0x	0.080.0x	0.060.0x	0.09-0.1x	0.140.0x	0.19-0.3x	0.53-0.1x	0.67
Debt-to-Equity	1.13+1.0x	0.130.0x	0.110.0x	0.12+0.1x	0.020.0x	0.02-0.2x	0.190.0x	0.17
FCF Margin	1.7%	N/A	N/A	-41.2%-14.0pp	-27.2%-25.7pp	-1.5%+43.1pp	-44.6%-58.8pp	14.2%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Halo Collective Inc HCANF

$15K

Avivagen VIVXF

$8K

Bloomios Inc BLMS

$6K

Veritas Farms VFRM

$16K

Onassis Holdings Corp ONSS

$26K

Where Item 9 Labs Ranks

Frequently Asked Questions

What is Item 9 Labs's annual revenue?

Item 9 Labs (INLB) reported $21.8M in total revenue for fiscal year 2022. This represents a -0.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Item 9 Labs's revenue growing?

Item 9 Labs (INLB) revenue declined by 0.8% year-over-year, from $21.9M to $21.8M in fiscal year 2022.

Is Item 9 Labs profitable?

No, Item 9 Labs (INLB) reported a net income of -$31.2M in fiscal year 2022.

What is Item 9 Labs's EBITDA?

Item 9 Labs (INLB) had EBITDA of -$21.5M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Item 9 Labs have?

As of fiscal year 2022, Item 9 Labs (INLB) had $86K in cash and equivalents against $7.2M in long-term debt.

What is Item 9 Labs's gross margin?

Item 9 Labs (INLB) had a gross margin of 33.6% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.

What is Item 9 Labs's return on equity (ROE)?

Item 9 Labs (INLB) has a return on equity of -50.3% for fiscal year 2022, measuring how efficiently the company generates profit from shareholder equity.

What is Item 9 Labs's free cash flow?

Item 9 Labs (INLB) recorded an outflow of $6.6M in free cash flow during fiscal year 2022. This represents a 20.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Item 9 Labs's operating cash flow?

Item 9 Labs (INLB) recorded an outflow of $2.3M in operating cash flow during fiscal year 2022, representing cash used by core business activities.

What are Item 9 Labs's total assets?

Item 9 Labs (INLB) had $110.8M in total assets as of fiscal year 2022, including both current and long-term assets.

What are Item 9 Labs's capital expenditures?

Item 9 Labs (INLB) invested $4.3M in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.

How many shares does Item 9 Labs have outstanding?

Item 9 Labs (INLB) had 100M shares outstanding as of fiscal year 2022.

What is Item 9 Labs's current ratio?

Item 9 Labs (INLB) had a current ratio of 0.09 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.

What is Item 9 Labs's debt-to-equity ratio?

Item 9 Labs (INLB) had a debt-to-equity ratio of 0.12 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Item 9 Labs's return on assets (ROA)?

Item 9 Labs (INLB) had a return on assets of -28.1% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.

How does Item 9 Labs's liquidity compare with its operating cash outflow?

At the end of fiscal year 2022, Item 9 Labs (INLB) held $86K in cash, cash equivalents and investments, and reported an operating cash outflow of $2.3M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Item 9 Labs's Altman Z-Score?

Item 9 Labs (INLB) has an Altman Z-Score of -1.71, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Item 9 Labs's Piotroski F-Score?

Item 9 Labs (INLB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Item 9 Labs's earnings high quality?

Item 9 Labs (INLB) reported a net loss of $31.2M while operations used $2.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Item 9 Labs cover its interest payments?

Item 9 Labs (INLB) reported an operating loss of $23.1M against $6.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.